Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
Plus Therapeutics (PSTV) has appointed Kyle Guse, J.D., M.B.A. to its Board of Directors, where he will serve as chair of the Audit Committee and on the Compensation Committee. Guse brings 30 years of professional experience, including a decade as CFO, General Counsel and Secretary at Atossa Therapeutics, a NASDAQ-listed company focused on breast cancer treatments.
Currently serving as Chief Legal Officer at NYSE-listed DDC Enterprise , Guse's background includes roles as a partner in top international law firms and as a Certified Public Accountant with a Big 4 firm. He holds a J.D. from Santa Clara University Law School and an M.B.A. from California State University, Sacramento.
Plus Therapeutics is developing targeted radiotherapeutics for central nervous system cancers, with key products including REYOBIQ™ and CNSide.
Plus Therapeutics (PSTV) ha nominato Kyle Guse, J.D., M.B.A., nel suo Consiglio di Amministrazione, dove ricoprirà il ruolo di presidente del Comitato di Revisione Contabile e farà parte del Comitato per la Remunerazione. Guse porta con sé 30 anni di esperienza professionale, inclusi dieci anni come CFO, Consigliere Legale Generale e Segretario presso Atossa Therapeutics, una società quotata al NASDAQ specializzata in trattamenti per il cancro al seno.
Attualmente Chief Legal Officer presso DDC Enterprise, quotata al NYSE, Guse ha ricoperto ruoli da partner in importanti studi legali internazionali ed è anche un Commercialista Certificato presso una delle Big 4. Ha conseguito un J.D. presso la Santa Clara University Law School e un M.B.A. presso la California State University di Sacramento.
Plus Therapeutics sta sviluppando radioterapie mirate per i tumori del sistema nervoso centrale, con prodotti chiave come REYOBIQ™ e CNSide.
Plus Therapeutics (PSTV) ha nombrado a Kyle Guse, J.D., M.B.A., en su Junta Directiva, donde ejercerá como presidente del Comité de Auditoría y formará parte del Comité de Compensación. Guse aporta 30 años de experiencia profesional, incluyendo una década como CFO, Asesor Legal General y Secretario en Atossa Therapeutics, una empresa cotizada en NASDAQ enfocada en tratamientos para el cáncer de mama.
Actualmente se desempeña como Chief Legal Officer en DDC Enterprise, cotizada en NYSE. Su trayectoria incluye roles como socio en importantes firmas legales internacionales y como Contador Público Certificado en una de las firmas Big 4. Posee un J.D. de la Facultad de Derecho de la Universidad de Santa Clara y un M.B.A. de la California State University, Sacramento.
Plus Therapeutics está desarrollando terapias radioterapéuticas dirigidas para cánceres del sistema nervioso central, con productos clave como REYOBIQ™ y CNSide.
Plus Therapeutics (PSTV)는 Kyle Guse, J.D., M.B.A.를 이사회에 임명했으며, 그는 감사위원회 의장과 보상위원회 위원으로 활동할 예정입니다. Guse는 30년의 전문 경력을 보유하고 있으며, 그중 10년은 유방암 치료에 중점을 둔 NASDAQ 상장 기업인 Atossa Therapeutics에서 CFO, 법률 고문 및 비서로 근무했습니다.
현재 NYSE 상장 기업인 DDC Enterprise의 최고법률책임자(Chief Legal Officer)로 재직 중인 Guse는 국제 유수 로펌의 파트너 및 빅4 회계법인의 공인회계사 경력을 가지고 있습니다. 그는 산타클라라 대학교 법학전문대학원에서 J.D. 학위를, 캘리포니아 주립대 새크라멘토에서 M.B.A.를 취득했습니다.
Plus Therapeutics는 중추신경계 암을 대상으로 하는 표적 방사선 치료제를 개발 중이며, 주요 제품으로는 REYOBIQ™와 CNSide가 있습니다.
Plus Therapeutics (PSTV) a nommé Kyle Guse, J.D., M.B.A., au sein de son conseil d'administration, où il assumera la présidence du comité d'audit et siègera au comité de rémunération. Guse apporte 30 ans d'expérience professionnelle, dont une décennie en tant que CFO, conseiller juridique général et secrétaire chez Atossa Therapeutics, une société cotée au NASDAQ spécialisée dans les traitements du cancer du sein.
Actuellement Chief Legal Officer chez DDC Enterprise, cotée au NYSE, Guse a également été associé dans des cabinets d'avocats internationaux de premier plan et expert-comptable agréé dans un cabinet du Big 4. Il est titulaire d'un J.D. de la Santa Clara University Law School et d'un M.B.A. de la California State University, Sacramento.
Plus Therapeutics développe des radiothérapies ciblées pour les cancers du système nerveux central, avec des produits clés tels que REYOBIQ™ et CNSide.
Plus Therapeutics (PSTV) hat Kyle Guse, J.D., M.B.A., in seinen Vorstand berufen, wo er den Vorsitz des Prüfungsausschusses übernimmt und im Vergütungsausschuss tätig sein wird. Guse bringt 30 Jahre Berufserfahrung mit, darunter ein Jahrzehnt als CFO, General Counsel und Sekretär bei Atossa Therapeutics, einem an der NASDAQ notierten Unternehmen, das sich auf Brustkrebsbehandlungen spezialisiert hat.
Derzeit ist er Chief Legal Officer bei DDC Enterprise, einem an der NYSE notierten Unternehmen. Guses Werdegang umfasst Positionen als Partner in führenden internationalen Anwaltskanzleien sowie als Wirtschaftsprüfer bei einer der Big 4. Er hat einen J.D. von der Santa Clara University Law School und einen M.B.A. von der California State University, Sacramento.
Plus Therapeutics entwickelt zielgerichtete Radiotherapeutika für Krebsarten des zentralen Nervensystems, mit Schlüsselprodukten wie REYOBIQ™ und CNSide.
- Addition of experienced biotech executive with 30 years of financial and operational expertise
- Strengthened board oversight with new Audit Committee chair
- Enhanced leadership team with expertise in both NASDAQ-listed companies and healthcare sector
- None.
HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company’s Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee.
“Kyle’s decades of financial, transactional and operational experience in our industry will make an immediate and positive impact to Plus’ board of directors,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “Furthermore, in his role as audit chair, Kyle will be a force in the successful execution of Plus’ ambitious business plan and driving stockholder value.”
Mr. Guse is an executive with 30 years of professional experience leading the world’s most innovative companies. For over a decade he served as Chief Financial Officer, General Counsel and Secretary of Atossa Therapeutics, Inc., a NASDAQ-listed company developing a drug to prevent and treat breast cancer, which had previously developed and marketed medical devices, and that owned and operated a CLIA certified laboratory. Currently, he serves as Chief Legal Officer of DDC Enterprise Ltd., an NYSE-listed international consumer foods company.
Formerly, he was a partner and practiced corporate law at several of the top international law firms. Prior to that, he was a Certified Public Accountant with a Big 4 accounting firm. He earned his J.D. (cum laude) from Santa Clara University Law School and an M.B.A. from California State University, Sacramento, where he also earned his Bachelor of Science degree.
“Plus Therapeutics has multiple and significant opportunities in both the therapeutics and diagnostics markets with REYOBIQ™ (rhenium Re186 obisbemeda) and CNSide, and I believe it has tremendous potential to make an impact on the market,” said Mr. Guse. “I’m looking forward to collaborating closely with the Board and with management to help bring the Company to its full potential for stockholders, practitioners, and patients.”
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.
These statements include, without limitation, statements regarding the potential promise of REYOBIQ™, expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates; the Company’s clinical trials, including statements regarding the timing and characteristics of the ReSPECT-LM single dose and multi-dose clinical trials; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
CORE IR
investor@plustherapeutics.com
FAQ
What role will Kyle Guse take on Plus Therapeutics' (PSTV) Board of Directors?
What is Kyle Guse's experience in the biotech industry?
What are Plus Therapeutics' (PSTV) main product candidates?
What is Kyle Guse's current position outside of Plus Therapeutics?
